Month: August 2022

Paul Sekhri appointed as President, Chief Executive Officer and Board member.Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s industry experience to collaborate in overseeing TTP399 clinical trials.Entered into agreements with G42 Investments to purchase $25 million in stock, collaborate on clinical trials and exclusively license rights to develop and commercialize TTP399 in certain geographic markets by a G42 affiliate.HIGH POINT, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June 30, 2022, and provided an update on recent corporate...

Revenue Growth of 134% Year over Year, 108% Growth Compared to the Previous Quarter and Secures entry into Full-Risk Value Based Care in 2022 TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Skylight Health Group Inc. (NASDAQ: SLHG; TSXV: SLHG) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, today announced its financial results for the second quarter ended June 30, 2022.Doubles revenue to $16.1 million vs $7.7 million in the previous quarter and 134% Year over Year. Gross profit margin of 25%, down from the previous quarter of 44% primarily driven by the Capitated revenue from full-risk Value Based Care (“VBC”) contracts with the acquisition of NeighborMD (“NMD”). Capitated revenue has lower Gross Margins but much higher dollar contribution. Adjusted EBITDA loss improved by 19%...

Q2 2022 SaaS Recurring Revenue Up 23% Over Q2 2021 Q2 2022 Gross Margin Up 23% Over Q2 2021 R&D Operational Expenses Cut 57% from Q2 2021 Successful MARKET.live launch and SHOPFEST in July 2022Second quarter 2022 SaaS recurring revenue up 23% over prior year comparable quarter Second quarter 2022 gross profit margin up 23% over prior year comparable quarter Second quarter 2022 Total Digital revenue up 19% over prior year comparable quarter SaaS recurring revenue now accounts for 91% of Total Digital revenue – up from 88% in Q2 2021 SaaS recurring revenue now accounts for 82% of total revenue – up from 67% in Q2 2021 Total Digital revenue accounts for 90% of total revenue – up from 76% in Q2 2021 R&D expense down 57% from prior year comparable quarter and 13% since Q1 2022 Modified EBITDA1 improvement by $2.2 million over Q2...

WINNIPEG, Manitoba, Aug. 15, 2022 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for the three-month and six-month period ending June 30, 2022. Financial Highlights for the three-month period ending June 30, 2022Net revenue of $17.5 million for the second quarter of 2022, an increase of 4%, from $16.75 million for the same quarter last year.Sequential net revenue increased 40% versus $12.5 million for the three-month period ending March 31, 2022Gross profit of $4.6 million for the second quarter of 2022, a decrease of 6%, from $4.9 million for the same quarter last year. Net Loss from operations of $(3.4) million for the second quarter of 2022 versus a loss from operations of $(0.8) million for the same quarter last year. Adjusted...

TERRE HAUTE, Ind., Aug. 15, 2022 (GLOBE NEWSWIRE) — Hallador Energy Company (NASDAQ – HNRG) today reported a net loss of $3.4 million, ($.11) per share, adjusted EBITDA of $11.5 million for the quarter ended June 30, 2022. Brent Bilsland, President and Chief Executive Officer, stated, “In the second quarter, we improved our cost structure by ~$8/ton over Q1 and contracted for ~2.2 million tons of forward sales at over $125/ton, dramatically increasing our future sales prices. Additionally, we were successful in raising $10 million to add to our liquidity (with an additional $19 million following in Q3). All of these events, lowering our cost structure, increasing our sales prices, and adding to our liquidity greatly improve our current and future financial position. Also, during the quarter, we made significant progress toward...

On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global partnership for rights to Renazorb in China with Lee’s Pharmaceutical (HK) Ltd. to further advance global commercial strategy for product with a differentiated profile and ease of administration for CKD patients Expects to file regulatory submission to initiate a Phase 1 healthy volunteer study in 2H’22 with UNI-494, a novel proprietary drug targeting the SUR2 subunit of the mitochondrial KATP   channel activator LOS ALTOS, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the...

LONDON, Aug. 15, 2022 (GLOBE NEWSWIRE) — Ferroglobe PLC (NASDAQ: GSM) (“Ferroglobe”, the “Company”, or the “Parent”), a leading producer globally of silicon metal, silicon-based and manganese-based specialty alloys, today announced results for the second quarter 2022. FINANCIAL HIGHLIGHTSRecord Q2 2022 revenue of $840.8 million, up 17.6% over the prior quarter Record Q2 2022 Adjusted EBITDA of $303.2 million, up 25.7% over the prior quarter Adjusted EBITDA margin improvement of 234 basis points to 36.1% in Q2 2022, up from 33.7% the prior quarter Record net profit of $185.1 million (diluted earnings per share of $0.98), compared to net profit of $150.8 million (diluted earnings per share of $0.80) in Q1 2022 Net debt of $194 million at quarter end, significant decrease from $342 million at the end of Q1 Bolstered liquidity: total...

SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported its second quarter 2022 financial results and highlighted recent corporate progress. Recent Corporate ProgressMost recently in July, we completed a $5 million public offering. We continue to explore the possible effects of REVTx-99b for the treatment of allergies. Data from our preclinical and Phase 2 viral challenge clinical study (RVL-VRL01) suggest intranasal REVTx-200 may positively augment the immune response relative to vaccination alone and we anticipate preclinical data during the fourth quarter. We anticipate preclinical data for REVTx-300...

FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the second quarter of 2022. Second Quarter 2022 Financial Results All comparisons are made on a year-over-year basis.Revenues. The Company generated $312,860 and $31,441 in revenues for the three months ended June 30, 2022 and 2021, respectively. The increase in revenues was mainly due to the revenue generated from the clinical development service agreement signed between BioKey and Rgene. Operating Expenses increased by $285,043, or 14%, to $2,351,353 for the three months ended June 30, 2022 from $2,066,310 for the three months ended June 30, 2021....